Early changes in circulating cell free KRAS G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients.

Cloud P Paweletz Grace A Heavey Yanan Kuang Emily Durlacher Thian Kheoh Richard C Chao Alexander I Spira Konstantinos Leventakos Melissa Lynne Johnson Sai-Hong Ignatius Ou Gregory J Riely Kenna Anderes Wenjing Yang James G Christensen Pasi A Janne

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

These results support using early plasma response of KRAS G12C assessed at approximately 3 weeks to anticipate the likelihood of a favorable objective clinical response.

Keyphrases

wild type
cell free
single cell
cell therapy
mesenchymal stem cells
bone marrow